NASDAQ
22.25USD
-0.47 (-2.05%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.5B
P/E
—
EPS
—
Beta
1.54
52W range
10.25-29.65
Day range
21.73–22.93
Open
22.48
Prev close
22.72
Volume
1.3M
Avg volume
2.3M
Dividend
0.00
IPO
2013-11-14
https://www.marketbeat.com/instant-alerts/tandem-diabetes-care-maps-growth-plan-with-pharmacy-shift-and-tubeless-mobi-2026-08-18/ · 8/18/2026+0.80
https://seekingalpha.com/article/4903619-tandem-diabetes-care-inc-tndm-presents-at-bank-of-america-global-healthcare-conference-2026 · 5/13/2026+0.00
https://www.marketbeat.com/instant-alerts/tandem-diabetes-care-q1-earnings-call-highlights-2026-05-09/ · 5/9/2026+0.80
https://www.globenewswire.com/news-release/2026/03/27/3263782/0/en/Tandem-Diabetes-Care-Inc-Investigated-by-the-Portnoy-Law-Firm.html · 3/27/2026-1.00
https://www.defenseworld.net/2026/03/15/tandem-diabetes-care-inc-tndm-stock-position-raised-by-arrowmark-colorado-holdings-llc.html · 3/15/2026+0.40
https://www.fool.com/investing/2026/02/20/why-tandem-diabetes-care-stock-is-up-today/ · 2/21/2026+1.00
https://www.zacks.com/stock/news/2872747/tndm-q4-earnings-revenues-beat-estimates-gross-margin-stock-up?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2872747 · 2/20/2026+0.60
https://www.newsfilecorp.com/release/283125/ROSEN-NATIONAL-TRIAL-LAWYERS-Encourages-Tandem-Diabetes-Care-Inc.-Investors-to-Inquire-About-Securities-Class-Action-Investigation-TNDM · 2/8/2026-1.00
https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-tandem-diabetes-care-inc-investors-to-inquire-about-securities-class-action-investigation--tndm-302675392.html · 1/31/2026-1.00
https://www.globenewswire.com/news-release/2026/01/30/3229816/673/en/TNDM-Investor-News-If-You-Have-Suffered-Losses-in-Tandem-Diabetes-Care-Inc-NASDAQ-TNDM-You-Are-Encouraged-to-Contact-The-Rosen-Law-Firm-About-Your-Rights.html · 1/30/2026-1.00
https://www.newsfilecorp.com/release/281426/ROSEN-A-HIGHLY-RECOGNIZED-LAW-FIRM-Encourages-Tandem-Diabetes-Care-Inc.-Investors-to-Inquire-About-Securities-Class-Action-Investigation-TNDM · 1/25/2026-1.00
https://www.newsfilecorp.com/release/280773/ROSEN-GLOBAL-INVESTOR-COUNSEL-Encourages-Tandem-Diabetes-Care-Inc.-Investors-to-Inquire-About-Securities-Class-Action-Investigation-TNDM · 1/19/2026-1.00
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works